252 related articles for article (PubMed ID: 21638942)
21. Screening for epidermal growth factor receptor mutations in lung cancer.
Rosell R; Moran T; Queralt C; Porta R; Cardenal F; Camps C; Majem M; Lopez-Vivanco G; Isla D; Provencio M; Insa A; Massuti B; Gonzalez-Larriba JL; Paz-Ares L; Bover I; Garcia-Campelo R; Moreno MA; Catot S; Rolfo C; Reguart N; Palmero R; Sánchez JM; Bastus R; Mayo C; Bertran-Alamillo J; Molina MA; Sanchez JJ; Taron M;
N Engl J Med; 2009 Sep; 361(10):958-67. PubMed ID: 19692684
[TBL] [Abstract][Full Text] [Related]
22. EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects.
Soria JC; Mok TS; Cappuzzo F; Jänne PA
Cancer Treat Rev; 2012 Aug; 38(5):416-30. PubMed ID: 22119437
[TBL] [Abstract][Full Text] [Related]
23. EGFR mutations and EGFR tyrosine kinase inhibition in non-small cell lung cancer.
Miller VA
Semin Oncol Nurs; 2008 Feb; 24(1):27-33. PubMed ID: 18222149
[TBL] [Abstract][Full Text] [Related]
24. Epidermal growth factor receptor mutations are associated with gefitinib sensitivity in non-small cell lung cancer in Japanese.
Uramoto H; Sugio K; Oyama T; Ono K; Sugaya M; Yoshimatsu T; Hanagiri T; Morita M; Yasumoto K
Lung Cancer; 2006 Jan; 51(1):71-7. PubMed ID: 16198442
[TBL] [Abstract][Full Text] [Related]
25. Personalized medicine for non-small-cell lung cancer.
Mok TS; Zhou Q; Leung L; Loong HH
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1601-11. PubMed ID: 20942631
[TBL] [Abstract][Full Text] [Related]
26. EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer.
Shih JY; Gow CH; Yang PC
N Engl J Med; 2005 Jul; 353(2):207-8. PubMed ID: 16014893
[No Abstract] [Full Text] [Related]
27. EGFR kinase domain mutations - functional impact and relevance for lung cancer therapy.
Irmer D; Funk JO; Blaukat A
Oncogene; 2007 Aug; 26(39):5693-701. PubMed ID: 17353898
[TBL] [Abstract][Full Text] [Related]
28. EGFR inhibition in NSCLC: the emerging role of cetuximab.
Herbst RS
J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S41-51. PubMed ID: 19780245
[TBL] [Abstract][Full Text] [Related]
29. Long-term gefitinib treatment of occult lung carcinoma with multiple brain metastases.
Kobayashi T; Takeda M; Marumo S; Koshimo Y; Teranishi T; Higami Y; Kato M
Lung Cancer; 2013 Apr; 80(1):109-11. PubMed ID: 23279871
[No Abstract] [Full Text] [Related]
30. [Personalized treatment in non-small cell lung cancer].
Campos-Parra AD; Cruz-Rico G; Arrieta O
Rev Invest Clin; 2012; 64(4):377-86. PubMed ID: 23227588
[No Abstract] [Full Text] [Related]
31. [EGFR pathway and mechanism of action of tyrosine kinase inhibitors].
Zalcman G
Rev Pneumol Clin; 2007 Jan; 63(1 Pt 2):2S5-6. PubMed ID: 17242635
[No Abstract] [Full Text] [Related]
32. Safety profiles of erlotinib therapy in patients with advanced non-small-cell lung cancer.
Hotta K; Kiura K
Expert Rev Anticancer Ther; 2011 Jul; 11(7):991-7. PubMed ID: 21806322
[TBL] [Abstract][Full Text] [Related]
33. Activity of gefitinib in a non-small-cell lung cancer patient with both activating and resistance EGFR mutations.
Morabito A; Costanzo R; Rachiglio AM; Pasquale R; Sandomenico C; Franco R; Montanino A; De Lutio E; Rocco G; Normanno N
J Thorac Oncol; 2013 Jul; 8(7):e59-60. PubMed ID: 23774386
[No Abstract] [Full Text] [Related]
34. Activating germline R776H mutation in the epidermal growth factor receptor associated with lung cancer with squamous differentiation.
van Noesel J; van der Ven WH; van Os TA; Kunst PW; Weegenaar J; Reinten RJ; Kancha RK; Duyster J; van Noesel CJ
J Clin Oncol; 2013 Apr; 31(10):e161-4. PubMed ID: 23358982
[No Abstract] [Full Text] [Related]
35. Medicine. Why a new cancer drug works well, in some patients.
Marx J
Science; 2004 Apr; 304(5671):658-9. PubMed ID: 15118127
[No Abstract] [Full Text] [Related]
36. Modern treatment of lung cancer: case 2. Response to erlotinib after failure of gefitinib in a patient with advanced non-small-cell lung carcinoma.
Garfield DH
J Clin Oncol; 2005 Oct; 23(30):7738-40. PubMed ID: 16234533
[No Abstract] [Full Text] [Related]
37. Gefitinib. Still no convincing results in non-small cell lung cancer.
Prescrire Int; 2010 Jun; 19(107):113. PubMed ID: 20738034
[No Abstract] [Full Text] [Related]
38. The impact of epidermal-growth-factor-receptor mutations in response to lung-cancer therapy.
Dowell JE; Minna JD
Nat Clin Pract Oncol; 2004 Nov; 1(1):2-3. PubMed ID: 16264773
[No Abstract] [Full Text] [Related]
39. Mutations of the epidermal growth factor receptor in non-small cell lung cancer -- search and destroy.
Chan SK; Gullick WJ; Hill ME
Eur J Cancer; 2006 Jan; 42(1):17-23. PubMed ID: 16364841
[TBL] [Abstract][Full Text] [Related]
40. Targeting EGFR in non-small-cell lung cancer.
Doroshow JH
N Engl J Med; 2005 Jul; 353(2):200-2. PubMed ID: 16014890
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]